Futura Medical plc (FAMDF)
USD 0.12
(26.32%)
USD 0.12
(26.32%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.77 Million GBP | 7273.22% |
| 2022 | -24.73 Thousand GBP | -24.87% |
| 2021 | -19.8 Thousand GBP | 20.79% |
| 2020 | -25 Thousand GBP | -178.7% |
| 2019 | 31.77 Thousand GBP | 260.09% |
| 2018 | -19.85 Thousand GBP | -105.47% |
| 2017 | 362.72 Thousand GBP | 112.92% |
| 2016 | 170.36 Thousand GBP | 477.97% |
| 2015 | 29.47 Thousand GBP | -32.9% |
| 2014 | 43.92 Thousand GBP | -88.16% |
| 2013 | 370.9 Thousand GBP | 394.54% |
| 2012 | 75 Thousand GBP | -52.53% |
| 2011 | 158 Thousand GBP | 26.4% |
| 2010 | 125 Thousand GBP | 150.0% |
| 2009 | 50 Thousand GBP | -66.67% |
| 2008 | 150 Thousand GBP | 900.0% |
| 2007 | 15 Thousand GBP | 0.0% |
| 2006 | - GBP | -100.0% |
| 2005 | 2000.00 GBP | -98.46% |
| 2004 | 130 Thousand GBP | 0.0% |
| 2003 | - GBP | 0.0% |
| 2002 | - GBP | 0.0% |
| 2001 | - GBP | 0.0% |
| 2000 | - GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.41 Million GBP | 0.0% |
| 2024 Q1 | 2.41 Million GBP | 457.2% |
| 2023 Q1 | 454.53 Thousand GBP | 3775.95% |
| 2023 Q3 | 432.58 Thousand GBP | -48.73% |
| 2023 Q4 | 432.58 Thousand GBP | 0.0% |
| 2023 FY | 1.77 Million GBP | 7273.22% |
| 2023 Q2 | 843.77 Thousand GBP | 85.64% |
| 2022 Q4 | -12.36 Thousand GBP | 0.0% |
| 2022 Q2 | -12.36 Thousand GBP | 0.0% |
| 2022 Q1 | - GBP | 100.0% |
| 2022 FY | -24.73 Thousand GBP | -24.87% |
| 2022 Q3 | - GBP | 100.0% |
| 2021 Q3 | - GBP | 100.0% |
| 2021 Q2 | -11.45 Thousand GBP | 0.0% |
| 2021 FY | -19.8 Thousand GBP | 20.79% |
| 2021 Q1 | - GBP | 100.0% |
| 2021 Q4 | -8353.00 GBP | 0.0% |
| 2020 Q2 | -12.35 Thousand GBP | 0.0% |
| 2020 Q3 | - GBP | 100.0% |
| 2020 FY | -25 Thousand GBP | -178.7% |
| 2020 Q4 | -12.65 Thousand GBP | 0.0% |
| 2020 Q1 | - GBP | -100.0% |
| 2019 Q3 | 15.88 Thousand GBP | 302.15% |
| 2019 FY | 31.77 Thousand GBP | 260.09% |
| 2019 Q1 | - GBP | 0.0% |
| 2019 Q2 | -7860.00 GBP | 0.0% |
| 2019 Q4 | 15.88 Thousand GBP | 0.0% |
| 2018 Q3 | - GBP | 0.0% |
| 2018 FY | -19.85 Thousand GBP | -105.47% |
| 2018 Q2 | - GBP | 0.0% |
| 2018 Q1 | - GBP | -100.0% |
| 2018 Q4 | - GBP | 0.0% |
| 2017 Q2 | 181.27 Thousand GBP | -0.0% |
| 2017 Q1 | 181.27 Thousand GBP | 250.43% |
| 2017 Q4 | 85.00 GBP | 0.0% |
| 2017 FY | 362.72 Thousand GBP | 112.92% |
| 2017 Q3 | 85.00 GBP | -99.95% |
| 2016 Q1 | 33.45 Thousand GBP | 401.72% |
| 2016 FY | 170.36 Thousand GBP | 477.97% |
| 2016 Q3 | 51.73 Thousand GBP | 54.65% |
| 2016 Q2 | 33.45 Thousand GBP | 0.0% |
| 2016 Q4 | 51.73 Thousand GBP | 0.0% |
| 2015 Q1 | 8071.00 GBP | -61.26% |
| 2015 Q2 | 8070.00 GBP | -0.01% |
| 2015 Q4 | 6667.00 GBP | 0.0% |
| 2015 Q3 | 6667.00 GBP | -17.39% |
| 2015 FY | 29.47 Thousand GBP | -32.9% |
| 2014 Q2 | 1131.00 GBP | 0.0% |
| 2014 Q3 | 20.83 Thousand GBP | 1742.09% |
| 2014 FY | 43.92 Thousand GBP | -88.16% |
| 2014 Q4 | 20.83 Thousand GBP | 0.0% |
| 2014 Q1 | 1131.00 GBP | -95.51% |
| 2013 Q3 | 25.19 Thousand GBP | -84.28% |
| 2013 Q2 | 160.25 Thousand GBP | -0.0% |
| 2013 Q1 | 160.25 Thousand GBP | 0.0% |
| 2013 FY | 370.9 Thousand GBP | 394.54% |
| 2013 Q4 | 25.19 Thousand GBP | 0.0% |
| 2012 FY | 75 Thousand GBP | -52.53% |
| 2011 FY | 158 Thousand GBP | 26.4% |
| 2010 FY | 125 Thousand GBP | 150.0% |
| 2009 FY | 50 Thousand GBP | -66.67% |
| 2008 FY | 150 Thousand GBP | 900.0% |
| 2007 FY | 15 Thousand GBP | 0.0% |
| 2006 FY | - GBP | -100.0% |
| 2005 FY | 2000.00 GBP | -98.46% |
| 2004 FY | 130 Thousand GBP | 0.0% |
| 2003 FY | - GBP | 0.0% |
| 2002 FY | - GBP | 0.0% |
| 2001 FY | - GBP | 0.0% |
| 2000 FY | - GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -267.766% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -332.564% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 84.843% |
| GB Sciences, Inc. | -624.00 USD | 284430.929% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 1527.936% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 72843.952% |
| Biomind Labs Inc. | -15.42 Thousand USD | 11603.015% |
| ContraFect Corporation | -154 Thousand USD | 1252.094% |
| CSL Limited | 7.56 Billion USD | 99.977% |
| CytoDyn Inc. | -29 Thousand USD | 6218.017% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 106.877% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 3776.464% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 5295.388% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -904.885% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 98.51% |
| SQZ Biotechnologies Company | 9.79 Million USD | 81.885% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -2751.26% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 88.171% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -2599.344% |
| Mesoblast Limited | -35.16 Million USD | 105.045% |
| Marizyme, Inc. | 457.7 Thousand USD | -287.638% |
| Genus plc | 178.7 Million USD | 99.007% |
| Pharming Group N.V. | 220.1 Million USD | 99.194% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 16229.318% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -2211.363% |
| IMV Inc. | -962.29 Thousand USD | 284.374% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 557.863% |
| MultiCell Technologies, Inc. | 49.32 USD | -3597274.29% |
| ONE Bio Corp. | 20.12 Million USD | 91.184% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 95.594% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 93.721% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 255.419% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -2434.607% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 35928.453% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -1162.794% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 2162.381% |
| Enzolytics Inc. | 30.7 Thousand USD | -5677.729% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.84% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 444.838% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.567% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -57096.164% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 20134.158% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 2215.976% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 3648.45% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -79.581% |
| EV Biologics, Inc. | 48.9 Thousand USD | -3528.272% |
| Q BioMed Inc. | -8988.00 USD | 19839.931% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 81.54% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 96.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 88.498% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 1919.438% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 853092.788% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -187.378% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 381.561% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 15091.339% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -904.885% |
| Affymax, Inc. | 1.35 Million USD | -30.732% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 61.497% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | -8285.00 USD | 21514.906% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -294.235% |
| SYBLEU INC | 11.69 Thousand USD | -15069.502% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 655.301% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 575.664% |
| Neutra Corp. | 14.33 Thousand USD | -12276.875% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 2263.689% |
| PureTech Health plc | -1.6 Million USD | 210.682% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 277.203% |
| IXICO plc | 3.27 Million USD | 45.742% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 355.652% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 199.063% |
| CSL Limited | 7.7 Billion USD | 99.977% |
| Cellectis S.A. | 18 Thousand USD | -9756.806% |